Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME study of [14C]-RPT193 in healthy men
NCT06087978Phase 1Completed
- Sponsor
- RAPT Therapeutics
- Start
- Jul 2023
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zelnecirnon in atopic dermatitis (AD) and asthma, sponsored by RAPT Therapeutics. Primary endpoints: Route(s) of elimination 1 at 14 days, Route(s) of elimination 2 at 14 days and 2 more. Started Jul 2023; status: completed.
02
Drugs
zelnecirnon
03
Conditions
atopic dermatitis (AD)asthma
Beyond the preview
Go deeper on NCT06087978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06087978.